---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-004967"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T21:00:55.764027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ArriVent licenses ADC MRG007 from Lepu Biopharma; upfront $47M, total potential $1.16B

## Summary
- Exclusive global rights outside Greater China for MRG007, a preclinical ADC targeting GI cancers.
- Lepu Biopharma receives $47M in upfront and near-term milestones; eligible for up to $1.16B in total milestones plus tiered royalties.
- First IND submission planned for first half 2025; initial focus on CRC, pancreatic, and other GI cancers.
- ArriVent’s previously announced cash runway into 2026 remains unchanged despite upfront and R&D costs.
- MRG007 showed robust antitumor activity and favorable therapeutic index in preclinical and IND-enabling studies.

## SEC filing metadata
- accession: 0001104659-25-004967
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465925004967/0001104659-25-004967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465925004967/tm253966d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-004967
- JSON: https://secwatch.observer/filing/0001104659-25-004967.json
- Plain text: https://secwatch.observer/filing/0001104659-25-004967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.